Skip to main content

Table 5 Factors associated with significant liver fibrosis in patients with HCV (n = 365)

From: The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C

  Univariate analysis Multivariate analysis
Variable OR 95% CI P value OR 95% CI P value
Age (years) 1.075 1.054–1.097  < .0001* 1.103 1.073—1.134  < .0001*
Men /Women (n) 1.158 0.753–1.782 0.5037    
Type 2 diabetes (n) 2.532 1.412–4.545 0.0018*    
Dyslipidemia (n) 2.188 1.195–4.000 0.0112*    
High-blood pressure (n) 2.976 1.859–4.762  < .0001*    
Obesity (BMI ≥ 30) (n) 1.086 0.6741.748 0.7358    
Metabolic syndrome (n) 2.299 1.294–4.082 0.0046*    
Hypothyroidism (n) 1.869 0.9993.497 0.0504    
Previous alcohol use (n) 1.089 0.4932.404 0.8325    
HOMA-IR value ≥ 2.5 (n) 1.773 1.149–2.732 0.0096*    
AST (U/L) 1.025 1.016–1.034  < .0001*    
ALT (U/L) 1.025 1.017–1.033  < .0001* 1.028 1.017–1.038  < .0001*
Alkaline phosphatase (U/L) 1.029 1.018–1.040  < .0001* 1.019 1.006–1.032 0.0043*
GGT (U/L) 1.007 1.003–1.010  < .0001*    
Creatinine (mg/dL) 1.183 0.7201.943 0.5065    
Total cholesterol (mg/dL) 0.988 0.982–0.995 0.0002* 0.975 0.965–0.984  < .0001*
HDL (mg/dL) 0.993 0.980–1.006 0.2949    
LDL (mg/dL) 0.987 0.980–0.994 0.0004*    
Triglycerides (mg/dL) 0.997 0.993–1.001 0.1454    
PNPLA3 C / G allele (n) 1.013 0.659–1.557 0.9524    
TM6SF2 CT + TT / CC (n) 1.953 1.009–3.788 0.0471*    
  1. Logistic regression
  2. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CI: confidence interval; GGT: gamma glutamyl transferase; HCV: hepatitis C virus; HDL: high-density lipoprotein; HOMA-IR: Homeostatic Model of Assessment; LDL: low-density lipoprotein; OR: odds ratio
  3. *p value < 0.05